Association for Accessible Medicines

AAM

Providing on-line digital publications in the nature of reports, letters, fact sheets, and charts in the field of generic and biosimilar pharmaceuticals via the internet;Printed reports featuring information in the field of generic and biosimilar pharmaceuticals;ASSOCIATION FOR ACCESSIBLE MEDICINES;Association services, namely, promoting the interests of the generic and biosimilar pharmaceuticals industry and its member companies;

AAM ASSOCIATION FOR ACCESSIBLE MEDICINES

Providing on-line digital publications in the nature of reports, letters, fact sheets, and charts in the field of generic and biosimilar pharmaceuticals via the internet;The mark consists of the lower case letters aam, appearing in a much larger font and above the mixed case words Association for Accessible Medicines.;Printed reports featuring information in the field of generic and biosimilar pharmaceuticals;Color is not claimed as a feature of the mark.;Association services, namely, promoting the interests of the generic and biosimilar pharmaceuticals industry and its member companies;

ASSOCIATION FOR ACCESSIBLE MEDICINES

Providing on-line digital publications in the nature of reports, letters, fact sheets, and charts in the field of generic and biosimilar pharmaceuticals via the internet;Printed reports featuring information in the field of generic and biosimilar pharmaceuticals;Association services, namely, promoting the interests of the generic and biosimilar pharmaceuticals industry and its member companies;

B C

The mark consists of the letter B in the center of a larger letter C together with three circle designs in different sizes on the right.;Color is not claimed as a feature of the mark.;Association services, namely, promoting awareness of biosimilars in the United States with the intent of expanding access to and availability of biological medicines and improving health care; providing information to inform and support public policies that encourage awareness of, access to, and adoption of biosimilars; promoting the interest of biosimilars development and adoption by means of public advocacy;